Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10404575 | 0.83 | TSHR (0.46) | SRCL3MBTL1TDP1MEN1KMT2A | |
| Triphenyl Phosphate SCHEMBL1028391 | 0.82 | SRC (0.61) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| SCHEMBL31156364 | 0.82 | SRC (0.47) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL27956810 | 0.81 | CYP3A4 (0.50) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL18116 | 0.79 | SRC (0.64) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL28761613 | 0.79 | SRC (0.64) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL28557783 | 0.79 | SRC (0.64) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL483692 | 0.79 | SRC (0.64) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| SCHEMBL131239 | 0.77 | CYP3A4 (0.61) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL7746390 | 0.77 | SRC (0.61) | SRCL3MBTL1TDP1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5717088-A | REACTING WITH A CYANOPHOSPHATE IN THE PRESENCE OF AN ALKALI METAL CYANIDE | SANKYO COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | claimed |
| CN-106458881-B | Carotenoid derivatives, its pharmaceutically acceptable salt or its pharmaceutically acceptable esters or amides | 阿斯塔制药有限公司 | 2019-07-30 | — | — | CN | disclosed |
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | Asta Pharmaceuticals Co., Ltd. (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3147279-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | Fuji Chemical Industry Co., Ltd. (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | FUJI CHEMICAL INDUSTRIES CO., LTD. (JP) | 2017-03-23 | — | — | US | disclosed |
| US-20090149444-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| US-7514475-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-7504437-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504393-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080255095-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-5717088-A | REACTING WITH A CYANOPHOSPHATE IN THE PRESENCE OF AN ALKALI METAL CYANIDE | SANKYO COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| US-5698720-A | INTERMEDIATES FOR TESTOSTERONE 5-ALPHA-REDUCTASE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0567271-B1 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO CO (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
| EP-0725074-A2 | Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives | SANKYO COMPANY LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | disclosed |
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | NR2E3, NR3C2, NR5A1 | SRC 2231/4885L3MBTL1 4074/4885TDP1 4629/4885 |
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | NR2E3, NR3C2, NR5A1 | SRC 2231/4885L3MBTL1 4074/4885TDP1 4629/4885 |
| US-20090149444-A1 | Benzylamine analogues | HTR4, DRD4, SLC6A4 | SRC 2139/4885L3MBTL1 1051/4885TDP1 254/4885 |
| US-20080255095-A1 | Benzylamine analogues | NR4A3, NAT1, HRH4 | SRC 2151/4885L3MBTL1 2873/4885TDP1 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.